1. Clinical & Scientific Overview
Adapalene, Benzoyl Peroxide & Oral Isotretinoin (TIP-MED-000459, Reference Code [12.27]) is classified under
Dermatological Preparations as a Third-Generation Topical Retinoid, Bactericidal Oxidising Comedolytic & Systemic Retinoid for Acne Vulgaris (Schedule H | NLEM 2022 [Benzoyl Peroxide] | HIGH-ALERT TERATOGEN [Isotr..
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Registered Medical Practitioner).
Representative Indian Formulations (for identification only): Adapalene 0.1%: Adaferin (Galderma), Deriva-CMS (Glenmark); FDCs: Deriva-BPO / Epiduo (Adapalene 0.1% + Benzoyl Peroxide 2.5% — Antibiotic-Free!), Deriva-C (+ Clindamycin 1%). | Strengths: Adapalene Aqueous Microsphere Gel: **0.1% w/w** (15 g). Benzoyl Peroxide Gel/Wash: **2.5%**, 5% w/w (2.5% is equally effective as 5%/10% with 50% less skin irritation!). Oral Isotretinoin Softgel Capsules: **10 mg, 20 mg, 30 mg**
Standard hospital formulary strengths
3. Mechanism of Action & Pharmacodynamics
Established pharmacological class action (Third-Generation Topical Retinoid, Bactericidal Oxidising Comedolytic & Systemic Retinoid for Acne Vulgaris (Schedule H | NLEM 2022 [Benzoyl Peroxide] | HIGH-ALERT TERATOGEN [Isotr.): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Adapalene 0.
4. Therapeutic Indications & Evidence-Supported Uses
- Adapalene 0
- 1% & Benzoyl Peroxide 2
- 5%: First-line topical therapy for mild-to-moderate comedonal (blackheads/whiteheads) and papulopustular **Acne Vulgaris** (**Adapalene 0
- 1% + BPO 2
- 5% [Deriva-BPO / Epiduo]** normalises follicular keratinisation and kills *Cutibacterium acnes* via free-radical oxidation with **ZERO
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Topical Adapalene 0.1% / Deriva-BPO: Wash face with mild cleanser, wait 15–20 min until skin is completely dry, and apply a **SINGLE PEA-SIZED DOT** to the **ENTIRE acne-prone face** (forehead, cheeks, chin — NOT just individual pimples; (Duration: Topical Acne: **8 to 12 weeks** minimum (warn patient that early microcomedone purging in Weeks 2–4 is normal and full clearing takes 8–12 weeks!). Oral Isotretinoin: 16–24 weeks)
Administration & Meal Timing: Oral (PO), Parenteral (IV / IM / SC as specified), Topical / Cutaneous | Food & Meal Timing: Topical Adapalene: Apply at **BEDTIME** (retinoids increase UV sensitivity) and apply a non-comedogenic moisturiser + morning **SPF 30–50+ Sunscreen**! Oral Isotretinoin: Swallow softgel capsules whol. | Best Time of Day: Topical Adapalene: Bedtime (OD). Benzoyl Peroxide: Morning (or at Bedtime in Adapalene+BPO FDC). Oral Isotretinoin: With Lunch/Dinner
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Renal & Hepatic: Oral Isotretinoin is contraindicated in hepatic insufficiency and severe hyperlipidaemia
Renal & Hepatic: Oral Isotretinoin is contraindicated in hepatic insufficiency and severe hyperlipidaemia
Renal & Hepatic: Oral Isotretinoin is contraindicated in hepatic insufficiency and severe hyperlipidaemia
7. Contraindications, Precautions & High-Risk Warnings
- ABSOLUTE HUMAN TERATOGENICITY BOXED WARNING FOR ORAL ISOTRETINOIN (AND TOPICAL RETINOIDS IN PREGNANCY!): **Oral Isotretinoin is one of the most potent human teratogens known** — even a **SINGLE CAPSULE** taken during pregnancy carries a 25%–40% risk of catastrophic birth defects (**Craniofacial/Ear absence [anotia], Conotruncal Heart Defe
Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
8. Adverse Effects Profile
- Topical Adapalene & BPO: Mild erythema, peeling/scaling, dryness, and stinging during the first 2–4 weeks ('retinoid dermatitis' — managed by applying moisturiser first ['sandwich method'] and spacing to alternate nights)
- Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL ORAL ISOTRETINOIN CONTRAINDICATED INTERACTIONS: (1) **TETRACYCLINES (Doxycycline, Minocycline, Tetracycline) + Oral Isotretinoin = STRICTLY CONTRAINDICATED!** Both independently raise intracranial pressure
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.
Pharmacist Patient Counselling Points:
- SIX VITAL ACNE COUNTER RULES: (1) For Deriva/Epiduo gel: apply ONLY a **single pea-sized dot** across the whole dry face at bedtime (more gel does NOT clear pimples faster — it only burns the skin!), use a moisturiser + morning sunscreen, and wait 8–12 weeks for full results
Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Adapalene Aqueous Microsphere Gel: **0.1% w/w** (15 g). Benzoyl Peroxide Gel/Wash: **2.5%**, 5% w/w (2.5% is equally effective as 5%/10% with 50% less skin irritation!). Oral Isotretinoin Softgel Capsules: **10 mg, 20 mg, 30 mg**). Missed-Dose Rule: Skip if missed; never double dose
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.4] Olmesartan Medoxomil — Angiotensin II Receptor Blocker (ARB) (Ester Prodrug)
- [3.1] Amlodipine (as Amlodipine Besylate) — Dihydropyridine Calcium Channel Blocker (CCB); Arterial Vasodilat
- [3.2] Telmisartan — Angiotensin II Receptor Blocker (ARB) with Partial PPAR-gamma Ago
- [3.3] Losartan Potassium — Angiotensin II Receptor Blocker (ARB; selective AT1 antagonist)